Cofoe Medical's stock soared 5.06% intraday on Monday, marking a significant rebound in trading.

The surge is supported by the company's ongoing A-share buyback program, which signals management confidence in the company's intrinsic value. Additionally, Cofoe Medical reported strong Q1 revenue growth of 37.22% year-over-year, contributing to the post-IPO recovery after a turbulent debut on the Hong Kong Exchange.